AlzeCure Pharma - Progress on all fronts and evolving into Phase II
With fresh funding in place and the FDA’s response to a pre-IND application, AlzeCure is evolving into a Phase II company with the initiation of a Phase IIa study with ACD440, a topical TRPV1 antagonist, for pain. This will be the company’s most advanced clinical trial and a significant catalyst. Its most advanced asset in Alzheimer’s disease (AD), ACD856, a novel cognitive enhancer from its NeuroRestore platform, continues to advance through the multiple ascending dose (MAD) part of the Phase I study, with the latest data showing that the compound successfully crosses the blood-brain barrier. Full data from the MAD part should be released in mid-2022. Our updated valuation is SEK1.08bn or SEK21.3 per share (versus SEK22.4 per share previously).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.